title: Brain PET in the diagnosis of Alzheimer's disease.
abstract: OBJECTIVE
  The aim of this article was to review the current role of brain PET in the diagnosis of Alzheimer dementia. The characteristic patterns of glucose metabolism on brain FDG-PET can help in differentiating Alzheimer's disease from other causes of dementia such as frontotemporal dementia and dementia of Lewy body. Amyloid brain PET may exclude significant amyloid deposition and thus Alzheimer's disease in appropriate clinical setting.
  
  
  CONCLUSIONS
  FDG-PET and amyloid PET imaging are valuable in the assessment of patients with Alzheimer's disease.
authors.affiliation: *Post Doctorate Research Fellow in the Russell H. Morgan, Department of Radiology and Radiological Sciences at Johns Hopkins University in Baltimore, MD; †Nuclear Medicine Resident in the Russell H. Morgan, Department ofRadiology and Radiological Sciences at Johns Hopkins University in Baltimore, MD; ‡Associate Professor in the Russell H. Morgan, Department of Radiology and Radiological Sciences, Department of Oncology, Department of Otolaryngology-Head and Neck Surgery at Johns Hopkins School of Medicine, and the Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
authors.forename: Charles
authors.initials: C
authors.lastname: Marcus
authors.forename: Esther
authors.initials: E
authors.lastname: Mena
authors.forename: Rathan M
authors.initials: RM
authors.lastname: Subramaniam
mesh_terms: D000544:Alzheimer Disease / Q000000981:diagnostic imaging* / Q000209:etiology; D001921:Brain / Q000000981:diagnostic imaging*; D060825:Cognitive Dysfunction / Q000175:diagnosis; D057180:Frontotemporal Dementia / Q000000981:diagnostic imaging; D006801:Humans; D020961:Lewy Body Disease / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals
chemical_list: D019275:Radiopharmaceuticals